Literature DB >> 33876205

Marginal zone B cells mediate a CD4 T-cell-dependent extrafollicular antibody response following RBC transfusion in mice.

Patricia E Zerra1,2, Seema R Patel2, Ryan Philip Jajosky1,3, Connie M Arthur1, James W McCoy1, Jerry William Lynn Allen3, Satheesh Chonat2, Ross M Fasano1,2, John D Roback1, Cassandra D Josephson1,2, Jeanne E Hendrickson4, Sean R Stowell3.   

Abstract

Red blood cell (RBC) transfusions can result in alloimmunization toward RBC alloantigens that can increase the probability of complications following subsequent transfusion. An improved understanding of the immune mechanisms that underlie RBC alloimmunization is critical if future strategies capable of preventing or even reducing this process are to be realized. Using the HOD (hen egg lysozyme [HEL] and ovalbumin [OVA] fused with the human RBC antigen Duffy) model system, we aimed to identify initiating immune factors that may govern early anti-HOD alloantibody formation. Our findings demonstrate that HOD RBCs continuously localize to the marginal sinus following transfusion, where they colocalize with marginal zone (MZ) B cells. Depletion of MZ B cells inhibited immunoglobulin M (IgM) and IgG anti-HOD antibody formation, whereas CD4 T-cell depletion only prevented IgG anti-HOD antibody development. HOD-specific CD4 T cells displayed similar proliferation and activation following transfusion of HOD RBCs into wild-type or MZ B-cell-deficient recipients, suggesting that IgG formation is not dependent on MZ B-cell-mediated CD4 T-cell activation. Moreover, depletion of follicular B cells failed to substantially impact the anti-HOD antibody response, and no increase in antigen-specific germinal center B cells was detected following HOD RBC transfusion, suggesting that antibody formation is not dependent on the splenic follicle. Despite this, anti-HOD antibodies persisted for several months following HOD RBC transfusion. Overall, these data suggest that MZ B cells can initiate and then contribute to RBC alloantibody formation, highlighting a unique immune pathway that can be engaged following RBC transfusion.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33876205      PMCID: PMC8394907          DOI: 10.1182/blood.2020009376

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  7 in total

Review 1.  Epigenetic regulation of B cells and its role in autoimmune pathogenesis.

Authors:  Fan Xiao; Ke Rui; Xiaofei Shi; Haijing Wu; Xiaoyan Cai; Kathy O Lui; Qianjin Lu; Esteban Ballestar; Jie Tian; Hejian Zou; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2022-10-12       Impact factor: 22.096

2.  Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice.

Authors:  Connie M Arthur; Seema R Patel; Asish Sharma; Patricia E Zerra; Satheesh Chonat; Ryan P Jajosky; Ross M Fasano; Ravi Patel; Ashley Bennett; Xiaoxi Zhou; C John Luckey; Krystalyn E Hudson; Stephanie C Eisenbarth; Cassandra D Josephson; John D Roback; Jeanne E Hendrickson; Sean R Stowell
Journal:  Transfusion       Date:  2022-04-26       Impact factor: 3.337

3.  Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway.

Authors:  Seema R Patel; Taran S Lundgren; Wallace Hunter Baldwin; Courtney Cox; Ernest T Parker; John F Healey; Ryan P Jajosky; Patricia E Zerra; Cassandra D Josephson; Christopher B Doering; Sean R Stowell; Shannon L Meeks
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

4.  Full-Length Galectin-3 Is Required for High Affinity Microbial Interactions and Antimicrobial Activity.

Authors:  Shang-Chuen Wu; Alex D Ho; Nourine A Kamili; Jianmei Wang; Kaleb L Murdock; Richard D Cummings; Connie M Arthur; Sean R Stowell
Journal:  Front Microbiol       Date:  2021-10-08       Impact factor: 6.064

5.  Galectin-9 recognizes and exhibits antimicrobial activity toward microbes expressing blood group-like antigens.

Authors:  Anna V Blenda; Nourine A Kamili; Shang-Chuen Wu; William F Abel; Diyoly Ayona; Christian Gerner-Smidt; Alex D Ho; Guy M Benian; Richard D Cummings; Connie M Arthur; Sean R Stowell
Journal:  J Biol Chem       Date:  2022-02-09       Impact factor: 5.486

6.  Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity.

Authors:  Patricia E Zerra; Ernest T Parker; Wallace Hunter Baldwin; John F Healey; Seema R Patel; James W McCoy; Courtney Cox; Sean R Stowell; Shannon L Meeks
Journal:  Biomedicines       Date:  2022-07-18

7.  Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice.

Authors:  Vicente Escamilla-Rivera; Manjula Santhanakrishnan; Jingchun Liu; David R Gibb; James E Forsmo; Ellen F Foxman; Stephanie C Eisenbarth; C John Luckey; James C Zimring; Krystalyn E Hudson; Sean R Stowell; Jeanne E Hendrickson
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.